Please note that due to a system merger our fulfilment system will be down beginning September 22nd with an anticipated date to begin shipping orders October 10th. We would like to apologize for any inconvenience by offering you a special 20% discount on select products. Please use Promotional Code 12760. Click here for promotion details.
The European Journal of Cancer (EJC) is an international multidisciplinary oncology journal, which publishes original research, reviews, and editorial comments on basic and preclinical cancer research, translational oncology, clinical oncology - including medical oncology, paediatric oncology, radiation oncology, and surgical oncology, and cancer epidemiology and prevention.
The EJC is the official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO), the European Association for Cancer Research (EACR) and the European Society of Breast Cancer Specialists (EUSOMA).
Why publish your work in the EJC?
Efficient peer-review: The EJC's Editors and reviewers are committed to maintaining the high standards of the journal. All manuscripts submitted to the EJC will be evaluated by the journal's Editors. Some manuscripts may be rejected outright following this evaluation, allowing the authors to submit their work elsewhere. Those manuscripts which are judged as being eligible for consideration by the Editors will be subject to peer-review. The full peer-review policy for the EJC can be found here.
The EJC has an online submission and peer-review system to facilitate the submission and peer-review of submitted manuscripts. Authors are able to upload their manuscript quickly and track the status of their manuscript throughout the review process.
Online Publication as an Article-in-Press: All manuscripts that are accepted for publication in the EJC are published online as Articles-in-Press within 4 - 5 weeks of acceptance. Articles-in-Press can be cited using the unique digital object identifier (DOI) which is assigned to all papers. In addition, Articles-in-Press are indexed in PubMed.
The EJC's readership: The EJC is published in print and online and is available to more than 17,000 academic and clinical institutions, personal subscribers and members of the journal's Society Partners (the EORTC, ECCO, EACR and EUSOMA). In 2011 the journal had more than 83,000 articles downloaded per month from across the world.
The EJC has an iPad app, making each issue of the journal available to our readers in this format. Visit click here to find out more.
eTables of Contents: Our readers can elect to receive free eTables of Contents via email, which are sent out for each issue of the journal.
Abstracting and Indexing Coverage: The EJC is included in the leading abstracting and indexing services, including PubMed/MEDLINE, Current Contents/Clinical Medicine, the Science Citation Index, the Journal Citation Reports and Scopus.
HINARI: The EJC is part of HINARI (Health InterNetwork Access to Research Initiative) administered by the World Health Organisation. The HINARI Programme enables developing countries to gain access to one of the world's largest collections of biomedical and health literature.
Why read the EJC?
High quality original research and review articles: The EJC is a multidisciplinary journal, publishing high quality original research and review articles on basic and preclinical research, translational oncology, clinical oncology (medical, paediatric, radiation, surgical), and cancer epidemiology and prevention from across the world.
Guidelines: The EJC is privileged to publish selected treatment guidelines from the journal's Society Partners (the EORTC, ECCO, EACR and EUSOMA) and other groups.
Special Series: The EJC publishes special series of papers on linked topics of particular relevance and interest to the journal's readers.
EJC News and EJC News Focus: Each month, the journal publishes the EJC News, discussing and commenting on current issues in cancer, together with the EJC News Focus, a series of video interviews with key opinion leaders in oncology.View all Oncology titles